Jazz Pharmaceuticals plcJAZZEarnings & Financial Report
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Revenue
$1.0B
Gross Profit
N/A
Operating Profit
$199.4M
Net Profit
$168.6M
Gross Margin
N/A
Operating Margin
19.5%
Net Margin
16.5%
YoY Growth
6.9%
EPS
$2.49
Jazz Pharmaceuticals plc Q2 FY2024 Financial Summary
Jazz Pharmaceuticals plc reported revenue of $1.0B (up 6.9% YoY) for Q2 FY2024, with a net profit of $168.6M (up 61.4% YoY) (16.5% margin).
Key Financial Metrics
| Total Revenue | $1.0B |
|---|---|
| Net Profit | $168.6M |
| Gross Margin | N/A |
| Operating Margin | 19.5% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
Jazz Pharmaceuticals plc Q2 FY2024 revenue of $1.0B breaks down across 10 segments, led by Xywav at $368.5M (36.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Xywav | $368.5M | 36.0% |
| Epidiolex Epidyolex | $247.1M | 24.1% |
| Rylaze Enrylaze | $107.8M | 10.5% |
| Zepzelca | $81.0M | 7.9% |
| Xyrem | $62.2M | 6.1% |
| High Sodium AG Oxybate Product Royalty Revenue | $54.2M | 5.3% |
| Other | $51.8M | 5.1% |
| Vyxeos | $43.0M | 4.2% |
| Other Royalty And Contract Revenues | $5.5M | 0.5% |
| Other Products | $2.7M | 0.3% |
Jazz Pharmaceuticals plc Revenue by Segment — Quarterly Trend
Jazz Pharmaceuticals plc revenue by segment across the last 4 reported quarters, showing how each business line (such as Xywav and Epidiolex Epidyolex) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Xywav | $465.5M | $431.4M | $415.3M | $344.8M |
| Epidiolex Epidyolex | — | $302.6M | $251.7M | $217.7M |
| Rylaze Enrylaze | $108.2M | $99.9M | $100.7M | $94.2M |
| Zepzelca | $90.4M | $79.3M | $74.5M | $63.0M |
| Xyrem | $37.8M | $35.7M | $35.3M | $37.2M |
Jazz Pharmaceuticals plc Annual Revenue by Year
Jazz Pharmaceuticals plc annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.3B).
| Year | Annual Revenue |
|---|---|
| 2025 | $4.3B |
| 2024 | $4.1B |
| 2023 | $3.8B |
| 2022 | $3.7B |
Jazz Pharmaceuticals plc Quarterly Revenue & Net Profit History
Jazz Pharmaceuticals plc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.2B | +10.1% | $203.5M | 17.0% |
| Q3 FY2025 | $1.1B | +6.7% | $251.4M | 22.3% |
| Q2 FY2025 | $1.0B | +2.1% | $-718.5M | -68.7% |
| Q1 FY2025 | $897.8M | -0.5% | $-92.5M | -10.3% |
| Q4 FY2024 | $1.1B | +7.5% | $191.1M | 17.6% |
| Q3 FY2024 | $1.1B | +8.5% | $215.1M | 20.4% |
| Q2 FY2024 | $1.0B | +6.9% | $168.6M | 16.5% |
| Q1 FY2024 | $902.0M | +1.0% | $-14.6M | -1.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $902.0M | $1.02B | $1.05B | $1.09B | $897.8M | $1.05B | $1.13B | $1.20B |
| YoY Growth | 1.0% | 6.9% | 8.5% | 7.5% | -0.5% | 2.1% | 6.7% | 10.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $11.33B | $11.36B | $12.26B | $12.01B | $11.53B | $10.94B | $11.36B | $11.66B |
| Liabilities | $7.63B | $7.60B | $8.08B | $7.92B | $7.36B | $7.24B | $7.40B | $7.34B |
| Equity | $3.70B | $3.76B | $4.17B | $4.09B | $4.17B | $3.71B | $3.96B | $4.32B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $267.2M | $331.4M | $398.7M | $398.6M | $429.8M | $88.9M | $474.6M | $362.5M |